11-20-2013, 03:07 AM
CEO: ["An analyst at Rodman and Renshaw, studied our X-22 smoking cessation segment extensively, and concluded that our company's potential valuation, based only on our X-22 product and not including any value of our assets on the tobacco product side of our company, would be $5 per share"]

